GlassScriptPhysician profile
Karis Lee
NPI 1568004612
$12,957.08
in general payments reported to CMS, 2019-2025
40 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,311 · 2022: $4,891 · 2023: $800 · 2024: $940 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,955.78 | 2021-2022 | |
| Abbvie INC. | $1,423.20 | 2021-2023 | |
| Horizon Therapeutics Plc | $837.69 | 2021-2023 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $782.72 | 2021-2025 | Breztri, Airsupra |
| Genzyme Corporation | $621.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $595.05 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $593.48 | 2021-2022 | |
| Janssen Biotech, INC. | $561.02 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $492.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $436.12 | 2021-2023 | |
| Pfizer INC. | $416.07 | 2021-2022 | |
| Gilead Sciences, INC. | $374.30 | 2022-2025 | Livdelzi, Epclusa |
| Neurocrine Biosciences, INC. | $358.81 | 2023-2025 | Ingrezza |
| Lilly USA, LLC | $320.69 | 2021-2022 | |
| Ucb, INC. | $255.48 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karis Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.